CD8A and cancer: These findings illuminate the potential significant roles of the low-biomass tumor microbiome in anti-tumor immunity and cancer metabolism, and lay the groundwork for further studies assessing whether these CD8+ TIL-associated microbial taxa and metabolites could serve as biomarkers or therapeutic agents for immunotherapy, increasing its efficacy in TNBC or expanding its usage in other BC subtypes.